ArticleTherapeutic advances in neurological disorders2010
Practical considerations on the use of rituximab in autoimmune neurological disorders.
Article in Therapeutic advances in neurological disorders, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.Frontiers in medicine · 2025Pooled it
- Coexistence of anti-GluK2 and anti-LGI1 antibodies in a patient with autoimmune encephalitis: a rare case report and literature review.BMC neurology · 2026Review
- Type 1 Diabetes and Other Autoimmune Diseases-Epidemiology, Pathophysiology and Screening.Endocrinology, diabetes & metabolism · 2026Review
- Autoimmune encephalitis.Nature reviews. Disease primers · 2025Review
- Long-Term Adverse Events of Rituximab in Multiple Sclerosis Patients, Isfahan, Iran.International journal of preventive medicine · 2025Article
- An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes.Frontiers in neurology · 2023Review
- Intravenous immunoglobulin bridging to rituximab in NMDAR encephalitis patients non-responders to first-line treatments.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.Drugs · 2022Review
- Leukoencephalopathy During Daratumumab-Based Therapy: A Case Series of Two Patients with Multiple Myeloma.OncoTargets and therapy · 2022Article
- The preventive Effectiveness of Rituximab in Pediatric Autoimmune and Inflammatory CNS Diseases Relapse: an Iranian Experience.Iranian journal of child neurology · 2022Article
- Reconstitution of the immune system and clinical correlates after stem cell transplantation for systemic sclerosis.Frontiers in immunology · 2022Review
- Rituximab in Refractory Myasthenia Gravis: Experience in a Single Healthcare Center in Mexico.Cureus · 2021Article
- Monoclonal Antibodies as Neurological Therapeutics.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Immunotherapy in Autoantibody-Associated Psychiatric Syndromes in Adults.Frontiers in psychiatry · 2021Review
- Neuropsychiatric Disorders Due to Limbic Encephalitis: Immunologic Aspect.International journal of molecular sciences · 2020Review
- Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study.Journal of neurology · 2019Article
- Immunotherapy in myasthenia gravis in the era of biologics.Nature reviews. Neurology · 2019Review
- Rituximab Treatment inSultan Qaboos University medical journal · 2018Article
- Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies.Therapeutic advances in neurological disorders · 2018Review
- Treatment strategies for autoimmune encephalitis.Therapeutic advances in neurological disorders · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rituximab (Mabthera, Rituxan) is a chimeric human/murine monoclonal antibody against CD-20 surface antigen expressed on B-cells. Rituximab, by causing B-cell depletion, appears to be effective in several autoimmune disorders; it has been approved for rheumatoid arthritis and is a promising new agent in the treatment of several autoimmune neurological disorders. A controlled study in patients with relapsing remitting multiple sclerosis has shown that rituximab significantly reduces the number of new MRI lesions and improves clinical outcome; it also showed some promise in a subset of patients with primary progressive MS. The drug is also effective in a number of patients with Devic's disease, myasthenia gravis, autoimmune neuropathies, and inflammatory myopathies. The apparent effectiveness of rituximab has moved B-cells into the center stage of clinical and laboratory investigation of autoimmune neurological disorders. We review the evidence-based effectiveness of rituximab in neurological disorders based on controlled trials and anecdotal reports, including our own experience, and address the immunobiology of B-cells in autoimmune central nervous system (CNS) and peripheral nervous system (PNS) disorders. In addition, we provide practical guidelines on how best to use this drug in clinical practice and highlight its potential toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.